Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 In Vitro
Preprint
Abstract
Ribavirin is a guanosine analog and has a broad-spectrum antiviral activity against RNA viruses. Based on this, we aimed to show the anti-SARS-CoV-2 activity of this drug molecule via in vitro, in silico and molecular techniques. Ribavirin showed antiviral activity in Vero E6 cells following SARS-CoV-2 infection. In silico analysis suggested that Ribarivin has a broad-spectrum impact on Vero E6 cells. According to the detailed molecular techniques, Ribavirin was shown to decrease TMPRSS2 expression both at mRNA and protein level 48 hours after treatment. The suppressive effect of Ribavirin in ACE2 protein expression was shown to be dependent on cell types. Finally, proteolytic activity assays showed that Ribavirin also showed an inhibitory effect on TMPRSS2 enzyme. As a conclusion, Ribavirin is a potential antiviral drug for the treatment against SARS-CoV-2, and it interferes with the effect of TMPRSS2 and ACE2 expression.Keywords
All Related Versions
- Published version: Canadian Journal of Physiology and Pharmacology, 99 (5), 449.
This publication has 27 references indexed in Scilit:
- Ongoing Clinical Trials for the Management of the COVID-19 PandemicTrends in Pharmacological Sciences, 2020
- The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?Molecular Cancer Therapeutics, 2019
- Clinical Outcomes of Paramyxovirus Infections in Lung Transplant Recipients Treated With Oral Ribavirin: A Two-Center Case SeriesExperimental and Clinical Transplantation, 2019
- Restriction of H1N1 influenza virus infection by selenium nanoparticles loaded with ribavirin via resisting caspase-3 apoptotic pathwayInternational Journal of Nanomedicine, 2018
- Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trialThe Lancet Infectious Diseases, 2017
- Management of RSV infections in adult recipients of hematopoietic stem cell transplantationBlood, 2011
- The Anti-Yellow Fever Virus Activity of Ribavirin Is Independent of Error-Prone ReplicationMolecular Pharmacology, 2006
- Mechanisms of action of ribavirin against distinct virusesReviews in Medical Virology, 2005
- Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplantsThe Hematology Journal, 2004
- Design, synthesis, and broad spectrum antiviral activity of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosidesJournal of Medicinal Chemistry, 1972